Abstract #1115
cPLA2 inhibition affects the relationship between vascular function and structure in a patient-derived breast cancer model: a correlation study of DCE-MRI vs. micro-CT
Eugene Kim 1 , Astrid Jullumstr Feuerherm 2,3 , Berit Johansen 2,3 , Olav Engebraaten 4 , Gunhild Mari Mlandsmo 4 , Tone Frost Bathen 1 , and Siver Andreas Moestue 1
1
MR Cancer Group, Department of Circulation
and Medical Imaging, Norwegian University of Science and
Technology, Trondheim, Norway,
2
Department
of Biology, Norwegian University of Science and
Technology, Trondheim, Norway,
3
Avexxin
AS, Trondheim, Norway,
4
Department
of Tumor Biology, Institute for Cancer Research, Oslo
University Hospital, Oslo, Norway
DCE-MRI and ex vivo micro-CT angiography were used to
investigate the relationship between tumor vascular
function and structure, and the effect of a cytosolic
phospholipase A2 (cPLA2) inhibitor (AVX235, Avexxin AS)
on this relationship, in a patient-derived breast cancer
model. In control tumors (n=7), there were good
correlations between Ktrans and vascular surface area
(SA) (r=0.67) and between vp and SA (r=0.7). In
AVX235-treated tumors (n=9), these correlations were
weaker (r=0.25 and 0.33, respectively). This suggests
that cPLA2 inhibition modulated the link between
vascular structure and function and had a spatially
heterogeneous effect on blood flow and/or vessel
permeability.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
